

**Amendment to the Claims:**

The following listing of claims will replace all prior versions of the claims:

**Listing of Claims:**

1. (Previously presented) A model mouse showing symptoms of diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, wherein the model mouse is obtained by immunizing with type IV collagen a homozygous and nonchimeric mouse whose endogenous genes that code for FcγRIIB are inactivated by genetic mutation and whose function of expressing FcγRIIB is impaired.

2. (Cancelled)

3. (Previously presented) A method for screening a remedy for improving symptoms of diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, comprising the steps of:

1) administering a test substance to a model mouse showing the symptoms of diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody, wherein the model mouse is obtained by immunizing with type IV collagen a homozygous and nonchimeric mouse whose endogenous genes that code for FcγRIIB are inactivated by genetic mutation,

2) determining at least one exhibition among diffuse alveolar hemorrhage, glomerulonephritis, and the appearance of antikidney glomerular basement membrane antibody,

3) performing a comparative evaluation with said model mouse used as control to which a test substance is not administered;

wherein a decrease in the severity of at least one said symptom in the model mouse to which the test substance is administered compared to the model mouse to which the test substance is

Application No. 10/009,950

not administered indicates that the test substance is effective.

4-13. (Cancelled)